Meet the Team

The Glo-BNHL trial is co-ordinated by the Children’s Cancer Trials Team (CCTT) based within the Cancer Research Clinical Trials Unit (CRCTU) at the University of Birmingham.

The Chief Investigator and the Chief Biostatistician are based at the University of Birmingham. Both work closely with the trial team.

Treatment Arm Lead Investigators contribute to the Glo-BNHL trial by acting as deputies for the Chief Investigator’s for a specific treatment arm of the trial. There are two Lead Investigators for each arm, and two Early Career Investigators in each arm support them.

The Trial Management Group (TMG) is a group of professionals from many different fields and organisations. The TMG meets several times a year to assist with the overall management of the trial and to make important trial related decisions.

The international Trial Steering Committee (TSC) is a group of independent professionals, whose role is to provide overall supervision for the trial on behalf of the Trial Sponsor (University of Birmingham) and the Trial Funders (Cancer Research UK and Fight Kids Cancer). They make sure that the trial is performed in line with the high standards of International Conference on Harmonisation Good Clinical Practice (ICH-GCP), most importantly focusing on the safety and well-being of the children, adolescents and young people involved.

A Principal Investigator at each of the hospitals running the Glo-BNHL trial takes overall responsibility for making sure that the trial runs correctly at their hospital site.

Chief Investigator

Professor Amos Burke

Chief Investigator of the Glo-BNHL trial and Professor of Paediatric Oncology
Director of Cancer Research UK Clinical Trials Unit

Email
g.a.a.burke@bham.ac.uk

 

Chief Biostatistician

Professor Lucinda Billingham

Professor of Biostatistics
Director of Statistics, Cancer Research UK Clinical Trials Unit

Telephone
+44 (0)121 414 3790/ PA +44(0)121 414 4092

Email
l.j.billingham@bham.ac.uk

 

 

Treatment Arm Investigators

• Sarah Alexander
  Treatment Arm I Co-lead

• TBC
  Treatment Arm I Co-lead

• Charles Phillips
  Treatment Arm I Early Career Investigator

• Charlotte Rigaud
  Treatment Arm I Early Career Investigator

• Birte Wistinghausen
  Treatment Arm II Co-lead

• Auke Beishuizen
  Treatment Arm II Co-lead

• Emma Seaford
  Treatment Arm II Early Career Investigator

• James Ford
  Treatment Arm II Early Career Investigator

• Véronique Minard
  Treatment Arm III Co-lead

• Joerg Kruger
  Treatment Arm III Co-lead

• Keri Toner
  Treatmement Arm III Early Career Investigator

• Friederike Meyer-Wentrup
  Treatment Arm III Early Career Investigator

Trial Management Team

• Pamela Kearns 
  (Clinician, Sponsor representative), CRCTU

• Amos Burke
  (Chief Investigator, CRCTU)

• Lucinda Billingham
  (Chief Biostatistician, CRCTU)

• Emma Seaford
  (Clinician, Trial Management)

• Rebecca Bishop
  (Trial Management, CRCTU)

• Anna Lawson 
  (Trial Management, CRCTU)

• Ellie Williams
  (Trial Management, CRCTU)

• Rhianna Parsons 
  (Project Manager, CRCTU)

• Zahra Ahmed
  (Trial Management, CRCTU)

• Mahnoor Muzaffar
  (Trial Management, CRCTU)

• Shanna Maycock
  (Senior Biostatistician, CRCTU)

Trial Management Group

• Pamela Kearns (Clinician, Sponsor representative), CRCTU
• Amos Burke (Chief Investigator, CRCTU)
• Lucinda Billingham (Chief Biostatistician, CRCTU)
• Anna Lawson (Trial Management, CRCTU)
• Ellie Williams (Trial Management, CRCTU)
• Mahnoor Muzaffar (Trial Management, CRCTU)
• Zahra Ahmed (Trial Management, CRCTU)
• Shanna Maycock (Senior Biostatistician, CRCTU)
• Nicole Scobie (European Consumer Representative)
• Angela Lee (US Consumer Representative)
• Suzanne Turner (Biology Lead, UK Academic)
• Sarah Alexander (Treatment Arm I Co-lead, Canadian Academic)
• Treatment Arm I Co-lead, European Academic (TBC)
• Auke Beishuizen (Treatment Arm II Co-lead, European Academic)
• Birte Wistinghausen (Treatment Arm II Co-lead, US Academic)
• Véronique Minard (Treatment Arm III Co-lead, European Academic)
• Joerg Kruger (Treatment Arm III Co-lead, US Academic)
• Charlotte Rigaud (Treatment Arm I Early Career Investigator, European Academic)
• Charles Phillips (Treatment Arm I Early Career Investigator, US Academic)
• Emma Seaford (Treatment Arm II Early Career Investigator, UK Academic)
• James Ford (Treatment Arm II Early Career Investigator, US Academic)
• Friederike Meyer-Wenthrup (Treatment Arm III Early Career Investigator, European Academic)
• Keri Toner (Treatment Arm III Early Career Investigator, US Academic)
• Representatives from each NCC (TBC)
• Sub-study Leads (TBC)

Trial Steering Committee

• Lia Gore (Independent Chair, Clinician, US Academic)
• Pamela Kearns (Sponsor representative, Clinician, UK Academic)
• Amos Burke (Chief Investigator, CRCTU)
• Emma Seaford (Clinician, European Academic)
• Sarah Alexander (Clinician, Canadian Academic)
• Carl Allen (Clinician, US Academic)
• Auke Beishuizen (Clinician, European Academic)
• Lucinda Billingham (Statistician, CRCTU)
• Shanna Maycock (Statistician, CRCTU)
• Anne Auperin (Statistician, European Academic)
• Catherine Bollard (Clinician, US Academic)
• Victoria Buenger (US Consumer Representative)
• Willemijn Plieger-van Solkema (European Consumer Representative)
• Véronique Minard (Clinician, European Academic)
• Birte Wistinghausen (Clinician, US Academic)
• Anna Lawson (Trial Management, CRCTU)
• Ellie Williams (Trial Management, CRCTU)
• Zahra Ahmed (Trial Management, CRCTU)
• Mahnoor Muzaffar (Trial Management, CRCTU)